2024
Association of Race and Ethnicity with Prescriptions for Continuous Glucose Monitoring Systems Among a National Sample of Veterans with Diabetes on Insulin Therapy
Lipska K, Oladele C, Zawack K, Gulanski B, Mutalik P, Reaven P, Lynch J, Lee K, Shih M, Lee J, Aslan M. Association of Race and Ethnicity with Prescriptions for Continuous Glucose Monitoring Systems Among a National Sample of Veterans with Diabetes on Insulin Therapy. Diabetes Technology & Therapeutics 2024 PMID: 39177775, DOI: 10.1089/dia.2024.0152.Peer-Reviewed Original ResearchVeterans with diabetesAssociation of raceCross-sectional analysis of dataU.S. Veterans Health AdministrationNational sample of veteransNational sampleInsulin therapyVeterans Health AdministrationSystem-level factorsSample of veteransNon-Hispanic patientsSelf-reported raceContinuous glucose monitoringCross-sectional analysisContinuous glucose monitoring useRate of prescriptionMultivariate mixed-effects modelAfrican American patientsLatino patientsHealth AdministrationAlaska NativesType 2 diabetesPercentage of patientsSignificant disparitiesMixed-effects models
2023
Metformin prescription for U.S. veterans with prediabetes, 2010–2019
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee K, Heberer K, Lynch J, Streja E, Mutalik P, Cheung K, Concato J, Shih M, Lee J, Aslan M. Metformin prescription for U.S. veterans with prediabetes, 2010–2019. Journal Of Investigative Medicine 2023, 72: 139-150. PMID: 37668313, DOI: 10.1177/10815589231201141.Peer-Reviewed Original ResearchConceptsBody mass indexVeterans Health AdministrationIncident prediabetesHigh riskHealth AdministrationRetrospective observational cohort studyType 2 diabetes mellitusUse of metforminObservational cohort studyProportion of veteransMetformin prescribingGestational diabetesCohort studyMetformin prescriptionDiabetes mellitusDiabetes preventionMass indexCardiovascular diseaseMultivariable modelPrediabetesSubset of individualsMetforminU.S. veteransHealthcare systemVeterans
2022
A Population-Level Analysis of the Protective Effects of Androgen Deprivation Therapy Against COVID-19 Disease Incidence and Severity
Lee KM, Heberer K, Gao A, Becker DJ, Loeb S, Makarov DV, Gulanski B, DuVall SL, Aslan M, Lee J, Shih MC, Lynch JA, Hauger RL, Rettig M. A Population-Level Analysis of the Protective Effects of Androgen Deprivation Therapy Against COVID-19 Disease Incidence and Severity. Frontiers In Medicine 2022, 9: 774773. PMID: 35602518, PMCID: PMC9115469, DOI: 10.3389/fmed.2022.774773.Peer-Reviewed Original ResearchAndrogen deprivation therapyCOVID-19 outcomesSARS-CoV-2ADT patientsDeprivation therapyCancer patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testingMale veteransSevere COVID-19 outcomesMultivariable logistic regression modelingSARS-CoV-2 infectionSevere COVID-19 illnessCOVID-19 pathophysiologyCOVID-19 patientsCOVID-19 illnessCOVID-19 severityVeterans Health AdministrationCoronavirus disease-19Logistic regression analysisLogistic regression modelingCOVID-19COVID-19 incidenceMale patientsCOVID-19 disease incidenceDisease-19